Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant

PLUS THERAPEUTICS, INC.

Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.
Prior role: Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX) from Oct 2021 to Apr 2026.
Initial annual base salary of $460,000; target bonus of 40% of base salary.
Equity inducement: option for 20,000 shares vesting over 4 years (1-yr cliff) and 20,000 RSUs vesting over 3 years.
Severance on involuntary termination: 12 months' salary plus target bonus, plus vesting acceleration on 9 months of unvested equity.

item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-148920
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2026-04-09T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.945203+00:00
generated_at: 2026-05-15T06:45:34.348773+00:00
sec_items: ["5.02", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-148920
json_url: https://secwatch.observer/filing/0001193125-26-148920.json
markdown_url: https://secwatch.observer/filing/0001193125-26-148920.md
text_url: https://secwatch.observer/filing/0001193125-26-148920.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/0001193125-26-148920-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/pstv-20260408.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-148920

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.